21金维他品牌怎么样 申请店铺

我要投票 21金维他在补铁锌硒行业中的票数:606 更新时间:2025-04-07
21金维他是哪个国家的品牌?「21金维他」是杭州赛诺菲民生健康药业有限公司旗下著名品牌。该品牌发源于浙江,由创始人张海敏在2009期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力21金维他品牌出海!通过在本页面挂载21金维他品牌的产品链接和联系邮箱,可以提高21金维他产品曝光!跨境电商爆单神器,目前只要100元/年哦~

21金维他怎么样

21金维他,1984年上市,是中国率先上市的多维元素产品。根据中国人营养状况和饮食习惯科学配比,均衡补充人体所需的21维生素和矿物质,采用国际一流生产线生产的健康产品。

“21金维他”是一种主要原料由21种维生素和微量元素组成的药品,是一种高级的维生素补充剂。21金维他里面含有维生素C和E,维生素C可以美白,增强抵抗力,抗衰老,维生素E有软化血管,抗衰老,美白,可以用于美容,祛除一定的斑痕。

杭州民生药业有限公司创建于1926年,是中国最早的四大西药厂之一。80余年来,民生药业一直专注于西药制药产业,见证了中国整个西药制药的历史。2006年被商务部评为第一批“中华老字号”企业。

公司主要生产处方药(抗肿瘤药、抗乙肝、心血管类)、OTC(含维生素和保健品类)、大输液(包括特种输液)以及原料药等四大品类的品种。21金维他在2004年被认定为“中国驰名商标”,并确立了在国内多维元素补充剂市场的领军品牌地位。另外公司在抗肿瘤及大输液等领域享有较高的市场声誉。

公司具有较强的产品开发能力和先进的质量保证体系。粉针剂、冻干粉针剂、大容量注射剂和片剂已获药品GMP证书。同时公司被杭州市政府有关部门确定为高效化学原料及各类新型制剂的研究和生产基地的高新技术企业。

80余年的积累和发展,民生药业成为了一家专业化、负责任的现代化制药公司,公司在2002年至2006年间成功实施了跳跃式发展战略;从2007年开始全面实施的国际化发展战略,将引领企业走向新的辉煌。打造一个经久不衰、生生不息、充满青春活力的百年民生是我们的追求!

杭州赛诺菲民生健康药业有限公司成立于2010年,是由全球领先的多元化医药健康企业赛诺菲与杭州民生药业集团共同组建的健康药业领域合资企业。这标志着赛诺菲正式进军充满活力的中国非处方药市场,同时也是全球第二大的非处方药市场。

作为全球领先的多元化医药健康企业,赛诺菲在健康药业领域通过不断并购,扩大其在全球的实力。进入中国健康药业市场成为赛诺菲支持中国预防保健事业的又一支柱。赛诺菲与长期合作的伙伴民生药业成立合资企业,旨在使21金维他®等品牌覆盖到各个市场,让更多的中国百姓享受到健康保障。

Kingvita, launched in 1984, is the first multi-dimensional element product to be launched in China. According to the scientific proportion of Chinese Nutrition and diet habits, we should supplement the 21 vitamins and minerals needed by human body in a balanced way, and adopt the health products produced by the world-class production line. "21 jinvita" is a kind of medicine composed of 21 kinds of vitamins and microelements, which is a kind of advanced vitamin supplement. Jinvita contains vitamin C and E. vitamin C can whiten, enhance resistance and resist aging. Vitamin E can soften blood vessels, resist aging and whiten. It can be used for beauty and remove certain spots. Founded in 1926, Hangzhou Minsheng Pharmaceutical Co., Ltd. is one of the first four Western pharmaceutical factories in China. For more than 80 years, Minsheng pharmaceutical industry has been focusing on Western pharmaceutical industry, witnessing the history of the whole western pharmaceutical industry in China. In 2006, it was awarded the first batch of "Chinese time-honored brand" enterprises by the Ministry of Commerce. The company mainly produces prescription drugs (anti-tumor drugs, anti hepatitis B drugs, cardiovascular drugs), OTC (including vitamins and health care products), large infusion (including special infusion) and APIs. In 2004, kingvita was recognized as "China's well-known trademark" and established its leading brand position in the domestic multi-dimensional element supplement market. In addition, the company enjoys a high market reputation in the fields of anti-tumor and infusion. The company has strong product development ability and advanced quality assurance system. Powder injection, freeze-dried powder injection, large volume injection and tablet have obtained GMP certificate. At the same time, the company is determined by the relevant departments of Hangzhou municipal government as a high-tech enterprise in the research and production base of high-efficiency chemical raw materials and various new preparations. With more than 80 years of accumulation and development, Minsheng pharmaceutical industry has become a professional and responsible modern pharmaceutical company. From 2002 to 2006, Minsheng pharmaceutical successfully implemented the leaping development strategy. The international development strategy, which has been fully implemented since 2007, will lead the enterprise to a new glory. It is our pursuit to build a centenary people's livelihood that is enduring, endless and full of youth and vitality! Hangzhou Sanofi Minsheng Health Pharmaceutical Co., Ltd., founded in 2010, is a joint venture in the field of health pharmaceutical jointly established by Sanofi, a global leading diversified pharmaceutical and health enterprise, and Hangzhou Minsheng Pharmaceutical Group. This marks Sanofi's official entry into the dynamic Chinese over-the-counter drug market, which is also the second largest over-the-counter drug market in the world. As a leading diversified medical and health enterprise in the world, Sanofi expands its global strength through continuous M & A in the field of health medicine. Entering the Chinese health pharmaceutical market has become another pillar of Sanofi's support for China's prevention and health care. Sanofi has set up a joint venture with Minsheng pharmaceutical, a long-term partner, aiming to make 21 jinvita ® and other brands reach all markets and more Chinese people enjoy health protection.

本文链接: https://brand.waitui.com/0d30c126b.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

耐克等品牌或将被迫提价

根据特朗普4月2日公布的关税清单,美国将对柬埔寨、越南、泰国等多个国家加征30%以上的对等关税,作为全球供应链上的重要一环,这些国家面临巨大的冲击。越南纺织服装协会的数据显示,2024年越南纺织品服装出口额达440亿美元,美国是其最大市场,耐克等服装品牌超过35%的产能聚集在越南。随着美国所谓“对等关税”措施即将实施,这些服装品牌将被迫提价。(央视财经)

2小时前

2025清明档新片总票房破3亿元

36氪获悉,据猫眼专业版数据,2025年4月6日17时20分,2025年清明档新片总票房破3亿元,《我的世界大电影》持续领跑,《向阳·花》《不说话的爱》分列二三位。

2小时前

紫金矿业:出售资产完成交割

36氪获悉,紫金矿业公告,公司澳大利亚全资子公司诺顿金田已收到现金1.56亿澳元及价值1000万澳元的8333万股MI6股票,交易已正式完成交割。标的公司持有BAB项目100%权益,截至2024年末,BAB项目拥有资源量金72吨,平均品位1.2克/吨。2014年9月,诺顿金田以约2500万美元对价收购标的公司100%股权。

2小时前

深交所公示第二届上市委、重组委委员候选人名单

36氪获悉,深圳证券交易所4月6日发布公告,日前,深交所启动了第二届上市审核委员会、第二届并购重组审核委员会组建工作。经相关单位推荐、履行相关程序,形成上市委、重组委委员候选人名单。为强化社会监督,保障上市委、重组委选聘工作公开、公平、公正,现就委员候选人名单予以公示,公示期为5个工作日。

2小时前

上交所公示第二届上市委、重组委委员候选人名单

36氪获悉,上海证券交易所发布公告,日前,上交所启动了第二届上市审核委员会、第二届并购重组审核委员会组建工作。经相关单位推荐、履行相关程序,形成上市委、重组委委员候选人名单。为强化社会监督,保障上市委、重组委选聘工作公开、公平、公正,现就委员候选人名单予以公示,公示期为5个工作日。

2小时前

本页详细列出关于安琪纽特的品牌信息,含品牌所属公司介绍,安琪纽特所处行业的品牌地位及优势。
咨询